{
  "ticker": "CCCC",
  "company_name": "C4 Therapeutics, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT04756726",
      "title": "Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1",
      "condition": "Multiple Myeloma, Lymphoma, Non-Hodgkin's",
      "start_date": "2021-04-27",
      "completion_date": "2026-03-31",
      "enrollment": 0,
      "sponsor": "C4 Therapeutics, Inc."
    },
    {
      "nct_id": "NCT05355753",
      "title": "A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Synovial Sarcoma, Soft Tissue Sarcoma",
      "start_date": "2022-03-25",
      "completion_date": "2023-12-19",
      "enrollment": 0,
      "sponsor": "C4 Therapeutics, Inc."
    },
    {
      "nct_id": "NCT07280013",
      "title": "A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Multiple Myeloma (MM)",
      "start_date": "2026-04",
      "completion_date": "2029-06",
      "enrollment": 0,
      "sponsor": "C4 Therapeutics, Inc."
    },
    {
      "nct_id": "NCT05668585",
      "title": "A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Solid Tumors, Melanoma, NSCLC, CRC, ATC",
      "start_date": "2022-12-08",
      "completion_date": "2025-11-05",
      "enrollment": 0,
      "sponsor": "C4 Therapeutics, Inc."
    },
    {
      "nct_id": "NCT07284758",
      "title": "A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Multiple Myeloma, Relapsed/Refractory Multiple Myeloma",
      "start_date": "2026-01",
      "completion_date": "2030-03",
      "enrollment": 0,
      "sponsor": "C4 Therapeutics, Inc."
    }
  ],
  "summary": {
    "total_trials": 5,
    "by_phase": {
      "PHASE1": 4,
      "PHASE2": 1
    },
    "by_status": {
      "ACTIVE_NOT_RECRUITING": 1,
      "TERMINATED": 1,
      "RECRUITING": 2,
      "COMPLETED": 1
    },
    "active_trials": 3,
    "completed_trials": 1,
    "conditions": [
      "Multiple Myeloma (MM)",
      "Multiple Myeloma, Lymphoma, Non-Hodgkin's",
      "Multiple Myeloma, Relapsed/Refractory Multiple Myeloma",
      "Solid Tumors, Melanoma, NSCLC, CRC, ATC",
      "Synovial Sarcoma, Soft Tissue Sarcoma"
    ],
    "lead_stage": "phase_2"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:17:21.449761",
    "search_query": "C4 Therapeutics, Inc.",
    "url": "https://clinicaltrials.gov/search?term=C4+Therapeutics,+Inc."
  }
}